Biotech Firm OKYO Pharma Closes US$2.5 Million IPO

Biotech firm OKYO Pharma Limited (Nasdaq: OKYO) closed on Thursday its initial public offering on the Nasdaq Capital Market. The firm was able to raise approximately US$2.5 million in its debut on the big board.

The offering consisted of 625,000 American depository shares at US$4.00 per share. The company’s shares are trading under the symbol “OKYO”.

Proceeds of the offering are intended for advancing the firm’s drug candidate OK-101 to filing an investigative new drug application, funding the drug’s phase 2 clinical trial, and for working capital and other general corporate purposes.

ThinkEquity acted as the sole bookrunner for the said offering.

The London-based life sciences company is focused on treating patients suffering from inflammatory eye diseases and ocular pain. It is presently developing its lead preclinical product candidate OK-101 to treat dry-eye disease.

OKYO Pharma last traded at US$3.00 on the Nasdaq.


Information for this briefing was found via Edgar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Silver’s Finally Breaking the System | Keith Neumeyer – First Majestic

The Best News for Gold Was the Drop! – Peter Grandich

McEwen Copper: The Los Azules Feasibility Study

Recommended

Steadright To Conduct Multi-Phased Exploration At Historic Goundafa Polymetallic Mine

Goliath Resources Drills 10.72 g/t Gold Over 7.83 Metres At Surebet

Related News

Education SPAC Aetherium Acquisition Prices US$100 Million IPO

Special purpose acquisition company Aetherium Acquisition Corp. (Nasdaq: GMFIU) started trading publicly on the Nasdaq...

Thursday, December 30, 2021, 02:24:00 PM

ESG SPAC GSR II Meteora Acquisition Prices Upsized US$275 Million IPO

Special purpose acquisition company GSR II Meteora Acquisition Corp (Nasdaq: GSRMU) started trading publicly on...

Friday, February 25, 2022, 03:04:00 PM

HempFusion Files For US$17 Million Initial Public Offering

HempFusion Wellness, the CBD firm that caused much excitement last year when it conducted a...

Thursday, October 22, 2020, 10:32:49 AM

Biotech SPAC BioPlus Acquisition Prices US$200 Million IPO

Special purpose acquisition company BioPlus Acquisition Corp. (Nasdaq: BIOSU) started trading publicly on the Nasdaq...

Monday, December 6, 2021, 02:19:00 PM

Cannabis-Focused Investment Firm Silver Spike Looks To Raise US$85.0 Million On Its Nasdaq IPO

Management investment firm Silver Spike Investment Corp. (Nasdaq: SSIC) announced on Friday the pricing of...

Monday, February 7, 2022, 02:25:00 PM